Search
formoterol/fumarate/mometasone
Indications:
- maintenance treatment of moderate to severe COPD
- predominantly benefits patients with elevated blood eosinophil count (> 300 x 10E6/L) [1]
Laboratory:
- complete blood count
- eosinophil count: > 300 x 10E6/L
General
LABA/LAMA glucocorticoid combination (triple therapy)
References
- Labaki WW, Rosenberg SR.
Chronic obstructive pulmonary disease.
Ann Intern Med 2020 Aug 4; 173:ITC17
PMID: 32745458
- Agusti A, Celli BR, Criner GJ et al.
Global Initiative for Chronic Obstructive Lung Disease 2023 Report:
GOLD executive summary.
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837.
PMID: 36856433 PMCID: PMC10111975 Free PMC article
https://www.atsjournals.org/doi/10.1164/rccm.202301-0106PP
Components
formoterol (Foradil, Perforomist)
fumarate
mometasone furoate (Asmanex, Nasonex)